Nicolas Folschweiller

1.1k total citations
28 papers, 635 citations indexed

About

Nicolas Folschweiller is a scholar working on Epidemiology, Public Health, Environmental and Occupational Health and Infectious Diseases. According to data from OpenAlex, Nicolas Folschweiller has authored 28 papers receiving a total of 635 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Epidemiology, 10 papers in Public Health, Environmental and Occupational Health and 9 papers in Infectious Diseases. Recurrent topics in Nicolas Folschweiller's work include Mosquito-borne diseases and control (10 papers), Hepatitis B Virus Studies (10 papers) and Cervical Cancer and HPV Research (8 papers). Nicolas Folschweiller is often cited by papers focused on Mosquito-borne diseases and control (10 papers), Hepatitis B Virus Studies (10 papers) and Cervical Cancer and HPV Research (8 papers). Nicolas Folschweiller collaborates with scholars based in Switzerland, United States and Belgium. Nicolas Folschweiller's co-authors include F. Pattus, Mohamed Abou‐Elwafa Abdallah, Isabelle J. Schalk, Hervé Celia, David Cobessi, Frank Struyf, P.V. Suryakiran, Pierre Van Damme, Olivier Van Der Meeren and Sylviane Poncelet and has published in prestigious journals such as Journal of Molecular Biology, JNCI Journal of the National Cancer Institute and Biochemistry.

In The Last Decade

Nicolas Folschweiller

27 papers receiving 621 citations

Peers

Countries citing papers authored by Nicolas Folschweiller

Since Specialization

Citations

This map shows the geographic impact of Nicolas Folschweiller's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nicolas Folschweiller with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nicolas Folschweiller more than expected).

Fields of papers citing papers by Nicolas Folschweiller

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nicolas Folschweiller. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nicolas Folschweiller. The network helps show where Nicolas Folschweiller may publish in the future.

Co-authorship network of co-authors of Nicolas Folschweiller

This figure shows the co-authorship network connecting the top 25 collaborators of Nicolas Folschweiller. A scholar is included among the top collaborators of Nicolas Folschweiller based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nicolas Folschweiller. Nicolas Folschweiller is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Immunogenicity and safety of the live-attenuated tetravalent dengue vaccine (TAK-003) co-administered with recombinant 9-valent human papillomavirus vaccine 2025 ·Vaccine ·(unknown), Suvaporn Anugulruengkitt, Keswadee Lapphra, Kriengsak Limkittikul, Auchara Tangsathapornpong, (unknown), Michael Hellwig, (unknown), Ron P. Schuring, Shibadas Biswal, Nicolas Folschweiller	0
2	Estimated Efficacy of TAK-003 Against Asymptomatic Dengue Infection in Children and Adolescents Participating in the DEN-301 Trial in Asia Pacific and Latin America 2025 ·The Journal of Infectious Diseases ·(unknown), Maria Theresa Alera, Lulu Bravo, Edson Duarte Moreira, Reynaldo Dietze, Ana Lúcia Lyrio de Oliveira, Veerachai Watanaveeradej, (unknown), Ivo Sonderegger, Vianney Tricou, Nicolas Folschweiller, Shibadas Biswal	3
3	Early onset of protection of the TAK-003 dengue vaccine: Data from the DEN-301 clinical trial 2024 ·Vaccine ·(unknown), Shibadas Biswal, Eric Lloyd, Vianney Tricou, Nicolas Folschweiller	7
4	Role of the dengue vaccine TAK-003 in an outbreak response: Modeling the Sri Lanka experience 2024 ·PLoS neglected tropical diseases ·LakKumar Fernando, (unknown), Pujitha Wickramasinghe, Asvini D. Fernando, Dulanie Gunasekera, (unknown), Mengya Liu, Inge Lefevre, Derek Wallace, Nicolas Folschweiller, Shibadas Biswal	3
5	Long term T cell response and safety of a tetravalent dengue vaccine in healthy children 2024 ·npj Vaccines ·(unknown), Heather Friberg, Xavier Sáez‐Llorens, Charissa Borja-Tabora, Shibadas Biswal, Ian Escudero, (unknown), Raphaël Gottardo, Manja Brose, (unknown), (unknown), Rodrigo DeAntonio, (unknown), (unknown), Nicolas Folschweiller, Jeffrey R. Currier, Mayuri Sharma, Vianney Tricou	9
6	Immunogenicity, Safety, and Efficacy of a Tetravalent Dengue Vaccine in Children and Adolescents: An Analysis by Age Group 2024 ·Clinical Infectious Diseases ·Charissa Borja-Tabora, LakKumar Fernando, Eduardo López‐Medina, Humberto Reynales, Luis Rivera, Xavier Sáez‐Llorens, Chukiat Sirivichayakul, Delia Yu, Nicolas Folschweiller, Kelley J. Moss, Martina Rauscher, Vianney Tricou, (unknown), Shibadas Biswal	7
7	A randomized phase 3 trial of the immunogenicity and safety of coadministration of a live-attenuated tetravalent dengue vaccine (TAK-003) and an inactivated hepatitis a (HAV) virus vaccine in a dengue non-endemic country 2023 ·Vaccine ·Vianney Tricou, (unknown), (unknown), Paul Collini, (unknown), (unknown), (unknown), Martina Rauscher, Manja Brose, Inge Lefevre, Nicolas Folschweiller, Derek Wallace	11
8	EFFICACY AND SAFETY OF TAKEDA'S TETRAVALENT DENGUE VACCINE CANDIDATE (TAK-003) AFTER 4.5 YEARS OF FOLLOW-UP: RESULTS FROM PARTICIPANTS IN ASIA 2023 ·International Journal of Infectious Diseases ·Andrew R. Green, Shyam Biswal, (unknown), Vianney Tricou, Nicolas Folschweiller	2
9	Safety and immunogenicity of a respiratory syncytial virus prefusion F protein (RSVPreF3) candidate vaccine in older Japanese adults: A phase I, randomized, observer-blind clinical trial 2023 ·Respiratory Investigation ·Shady Kotb, Miwa Haranaka, Nicolas Folschweiller, (unknown), (unknown), Nathalie De Schrevel, Marie‐Pierre David, Narcisa Mesaros, Veronica Hulstrøm	11
10	Effect of the Tetravalent Dengue Vaccine TAK-003 on Sequential Episodes of Symptomatic Dengue 2023 ·American Journal of Tropical Medicine and Hygiene ·Xavier Sáez‐Llorens, Shibadas Biswal, Charissa Borja-Tabora, LakKumar Fernando, Mengya Liu, Derek Wallace, Nicolas Folschweiller, Humberto Reynales, Inge Lefevre, (unknown)	14
11	Bridging the immunogenicity of a tetravalent dengue vaccine (TAK-003) from children and adolescents to adults 2023 ·npj Vaccines ·Inge Lefevre, Lulu Bravo, Nicolas Folschweiller, Eduardo López‐Medina, Edson Duarte Moreira, Francesco Nordio, Mayuri Sharma, Leslie Tharenos, Vianney Tricou, Veerachai Watanaveeradej, Peter Winkle, Shibadas Biswal	8
12	Reactogenicity, safety, and immunogenicity of chimeric haemagglutinin influenza split-virion vaccines, adjuvanted with AS01 or AS03 or non-adjuvanted: a phase 1–2 randomised controlled trial 2022 ·The Lancet Infectious Diseases ·Nicolas Folschweiller, Carline Vanden Abeele, Laurence Chu, Pierre Van Damme, Adolfo Garcı́a-Sastre, Florian Krammer, Raffael Nachbagauer, Peter Palese, Alicia Solórzano, Dan Bi, Marie‐Pierre David, Damien Friel, Bruce L. Innis, (unknown), Corey P. Mallett, (unknown), Bruno Salaun, Valérie Vantomme, (unknown), Frank Struyf	17
13	A ten-year study of immunogenicity and safety of the AS04-HPV-16/18 vaccine in adolescent girls aged 10-14 years 2019 ·Human Vaccines & Immunotherapeutics ·Tino F. Schwarz, Li‐Min Huang, Alejandra Valencia, (unknown), Cheng‐Hsun Chiu, Annabelle Decreux, Sylviane Poncelet, Naveen Karkada, Nicolas Folschweiller, Lan Lin, Gary Dubin, Frank Struyf	45
14	Efficacy of the AS04-Adjuvanted HPV16/18 Vaccine: Pooled Analysis of the Costa Rica Vaccine and PATRICIA Randomized Controlled Trials 2019 ·JNCI Journal of the National Cancer Institute ·Joseph E. Tota, Frank Struyf, Joshua N. Sampson, Paula González, Martin Ryser, Rolando Herrero, John Schussler, Naveen Karkada, Ana Cecilia Rodríguez, Nicolas Folschweiller, Carolina Porras, Mark Schiffman, John T. Schiller, Wim Quint, Aimée R. Kreimer, Cosette M. Wheeler, Allan Hildesheim, (unknown)	23
15	Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and 4vHPV vaccine administered according to two- or three-dose schedules in girls aged 9–14 years: Results to month 36 from a randomized trial 2017 ·Vaccine ·Ting Fan Leung, (unknown), Fong Seng Lim, Franck Thollot, Helen May Lin Oh, Bee Wah Lee, Lars Rombo, Ngiap Chuan Tan, Roman Rouzier, (unknown), P.V. Suryakiran, Marjan Hezareh, Florence Thomas, Nicolas Folschweiller, Frank Struyf	22
16	Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine administered according to 2- and 3-dose schedules in girls aged 9–14 years: Results to month 12 from a randomized trial 2015 ·Human Vaccines & Immunotherapeutics ·Ting Fan Leung, (unknown), Fong Seng Lim, Franck Thollot, Helen May Lin Oh, Bee Wah Lee, Lars Rombo, Ngiap Chuan Tan, Roman Rouzier, Damien Friel, (unknown), (unknown), P.V. Suryakiran, Marjan Hezareh, Nicolas Folschweiller, Florence Thomas, Frank Struyf	41
17	Characterization of 16 human G protein-coupled receptors expressed in baculovirus-infected insect cells 2005 ·Protein Expression and Purification ·(unknown), Markus Koglin, (unknown), Nicolas Folschweiller, Simon J. Dowell, (unknown)	51
18	The Crystal Structure of the Pyoverdine Outer Membrane Receptor FpvA from Pseudomonas aeruginosa at 3.6Å Resolution 2005 ·Journal of Molecular Biology ·David Cobessi, Hervé Celia, Nicolas Folschweiller, Isabelle J. Schalk, Mohamed Abou‐Elwafa Abdallah, F. Pattus	136
19	In vivo incorporation of selenomethionine in proteins using Pseudomonas aeruginosa as expression host: case study—the outer membrane receptor FpvA 2004 ·Protein Expression and Purification ·Nicolas Folschweiller, (unknown), Hervé Celia, Noëlle Potier, David Cobessi, Alain Van Dorsselaer, F. Pattus	3
20	Crystallization and preliminary X-ray analysis of the outer membrane pyoverdine receptor FpvA fromPseudomonas aeruginosa 2004 ·Acta Crystallographica Section D Biological Crystallography ·David Cobessi, Hervé Celia, Nicolas Folschweiller, Michaël Heymann, Isabelle J. Schalk, Mohamed Abou‐Elwafa Abdallah, F. Pattus	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact